Abstract
Gastric carcinogenesis is a complex multistep process involving genetic dysregulation of proto-oncogenes and tumorsuppressor genes, and has recently entered the era of microRNAs (miRNAs), a class of small non-coding RNAs that posttranscriptionally regulate gene expression and control various cellular functions. MicroRNAs are small (approximately 22 nucleotides) non-coding RNAs that play fundamental roles in diverse biological and pathological processes, including cell proliferation, differentiation, apoptosis, and carcinogenesis. MicroRNAs have been revealed to be involved in various stages of cancer development, showing that abnormal miRNA expressions play critical roles in modulating expression of known oncogenes or tumor suppressor genes during cancer progression. Therefore, microRNAs can perform the function of onco-miRs or tumor-suppressor-miRs in gastric carcinogenesis. This review summarizes a current understanding of the connection between miRNAs and gastric cancer. Additionally, this paper outlines the applications of miRNAs in clinical practice, such as diagnosis, prognosis, detection, and therapy of gastric cancer.
Keywords: microRNA, gastric cancer, next-generation sequencing (NGS), Epigenetic, prognostic signature, genetic dysregulation, proto-oncogenes, apoptosis, diagnosis, therapy
Current Pharmaceutical Design
Title:MicroRNA Dysregulation in Gastric Cancer
Volume: 19 Issue: 7
Author(s): Hung-Wei Pan, Sung-Chou Li and Kuo-Wang Tsai
Affiliation:
Keywords: microRNA, gastric cancer, next-generation sequencing (NGS), Epigenetic, prognostic signature, genetic dysregulation, proto-oncogenes, apoptosis, diagnosis, therapy
Abstract: Gastric carcinogenesis is a complex multistep process involving genetic dysregulation of proto-oncogenes and tumorsuppressor genes, and has recently entered the era of microRNAs (miRNAs), a class of small non-coding RNAs that posttranscriptionally regulate gene expression and control various cellular functions. MicroRNAs are small (approximately 22 nucleotides) non-coding RNAs that play fundamental roles in diverse biological and pathological processes, including cell proliferation, differentiation, apoptosis, and carcinogenesis. MicroRNAs have been revealed to be involved in various stages of cancer development, showing that abnormal miRNA expressions play critical roles in modulating expression of known oncogenes or tumor suppressor genes during cancer progression. Therefore, microRNAs can perform the function of onco-miRs or tumor-suppressor-miRs in gastric carcinogenesis. This review summarizes a current understanding of the connection between miRNAs and gastric cancer. Additionally, this paper outlines the applications of miRNAs in clinical practice, such as diagnosis, prognosis, detection, and therapy of gastric cancer.
Export Options
About this article
Cite this article as:
Pan Hung-Wei, Li Sung-Chou and Tsai Kuo-Wang, MicroRNA Dysregulation in Gastric Cancer, Current Pharmaceutical Design 2013; 19 (7) . https://dx.doi.org/10.2174/138161213804805621
DOI https://dx.doi.org/10.2174/138161213804805621 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors
Current Pharmaceutical Design Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs)
Current Gene Therapy HOX Genes as Potential Markers of Circulating Tumour Cells
Current Molecular Medicine ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design Regulation of Cellular Signal Transduction Pathways by the Extracellular Calcium-Sensing Receptor
Current Pharmaceutical Biotechnology Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Novel Anti-inflammatory Drugs from Marine Microbes
The Natural Products Journal Intelligent Drug Delivery Systems: Polymeric Micelles and Hydrogels
Mini-Reviews in Medicinal Chemistry HR MAS MR Spectroscopy in Metabolic Characterization of Cancer
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Molecular Markers of Angiogenesis and Metastasis in Lines of Oral Carcinoma after Treatment with Melatonin
Anti-Cancer Agents in Medicinal Chemistry Gut Permeability and Microbiota in Parkinson’s Disease: Role of Depression, Tryptophan Catabolites, Oxidative and Nitrosative Stress and Melatonergic Pathways
Current Pharmaceutical Design Furanodienone: An Emerging Bioactive Furanosesquiterpenoid
Current Organic Chemistry Acetylcholinesterase Enzyme Inhibitor Molecules with Therapeutic Potential for Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases
Current Protein & Peptide Science Regulators of Chemokine Receptor Activity as Promising Anticancer Therapeutics
Current Cancer Drug Targets Analytical Procedure for Determination of Cyclooxygenase-2 Inhibitors in Biological Fluids by High Performance Liquid Chromatography: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Determination of Usnic Acid Responsive miRNAs in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Molecular Signatures of Biomarkers in Cancer Development, Diagn osis, and its Prognostic Accuracy
Current Biomarkers (Discontinued) ANTI-ADHESION Evolves To a Promising Therapeutic Concept in Oncology
Current Medicinal Chemistry